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Abstract
Background: The current syphilis epidemic among urban men who have sex with men (MSM) has serious implications
for those co-infected with human immunodeficiency virus (HIV). Routine and frequent syphilis screening has the potential
to ensure early detection and treatment, minimize disease burden, and help control the ongoing spread of syphilis and
HIV. We aim to enhance syphilis screening among HIV-positive men by conducting a clinic-based intervention
that incorporates opt-out syphilis testing into routine HIV laboratory evaluation for this population. Trial objectives are to
determine the degree to which the intervention (1) increases the detection rate of untreated syphilis, (2) increases
screening coverage, (3) increases screening frequency, and (4) reaches men at highest risk according to sexual behaviors.
Methods/design: The trial is a pragmatic, stepped wedge cluster-randomized controlled trial that introduces the
intervention stepwise across four urban HIV clinics in Ontario, Canada. The intervention includes standing orders
for syphilis serological testing whenever a male in HIV care undergoes HIV viral load testing, which typically
occurs every 3–6 months. The control condition is the maintenance of current, provider-initiated syphilis testing
practice. Approximately 3100 HIV-positive men will be followed over 30 months. Test results will be obtained
from the centralized provincial laboratory in Ontario and will be supplemented by a standardized clinical worksheet
and medical chart review at the clinics. Detailed clinical, psychosocial, and behavioral data is available for a subset of
men receiving HIV care who are also participants of the province-wide Ontario HIV Treatment Network Cohort Study.
Process evaluation plans include audit and feedback of compliance of the participating centers to identify potential
barriers to the introduction of this type of practice into routine care. Health economic components include evaluation
of the impact and cost-effectiveness of the intervention.
Discussion: This trial will be the first of its kind in Canada and will provide evidence regarding the feasibility, clinical
effectiveness, and cost-effectiveness of a clinic-based intervention to improve syphilis screening among HIV-positive
men. Involvement of knowledge users in all stages of trial design, conduct, and analysis will facilitate scale-up should
the intervention be effective.
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Background
After years of decline, in many urban settings inter-
nationally, including Canada, syphilis has re-emerged as
a serious health burden among men who have sex with
men (MSM) [1–5]. Syphilis is caused by the bacterium
Treponema pallidum. Transmission occurs from an ac-
tive case via sexual activity involving oral, vaginal, or
anal mucosae [6]. For men who are co-infected with hu-
man immunodeficiency virus (HIV), transmission rates
may be increased, the response to treatment can be sub-
optimal [7, 8], the development of neurosyphilis may be
accelerated [9, 10], treatment decisions are more complex,
and HIV infectiousness may be enhanced [6, 11–13]. In
Ontario, lifetime syphilis prevalence among MSM in HIV
care was estimated to be 23.4 % as of 2009, and in 2010,
incidence of a new syphilis diagnosis was 4.3 per 100
person-years (PY), over 300 times greater than the rate of
0.01 per 100 PY reported for the general male population
[14]. Repeat diagnoses (reflecting repeat infections) of
syphilis were higher at 4.8 per 100 PY (95 % 3.7, 5.5).
These rates are under-estimates of true prevalence and in-
cidence because they reflect cases detected by routine
practice rather than by active screening programs.
Frequent syphilis screening has the potential to ensure
early detection and treatment of cases, minimize disease
burden for patients, and help control the ongoing spread
of syphilis and HIV [15, 16]. International guidelines
recommend syphilis screening among people with HIV at
least once per year, with some advising more frequent
testing at 3- to 6-month intervals [6, 17, 18]. Canadian
Sexually Transmitted Infection (STI) Guidelines recom-
mend screening for syphilis, gonorrhea, chlamydia, and
HIV at 3-month intervals even in the absence of symp-
toms—for individuals identified at “ongoing risk for STIs”
[6]. Preliminary mathematical models suggest that fre-
quent syphilis screening, at minimum twice per year,
could have substantial impacts on reducing syphilis trans-
mission among the most high-risk MSM [16, 19, 20].
Despite the guidelines, current levels of screening and
testing remain infrequent in many settings [21–23].
Screening is often limited to opportunistic screening
when men self-disclose sexual risk behavior. Diagnostic
tests are restricted to those presenting with signs or
symptoms and miss asymptomatic or mild cases in per-
sons who may not seek medical attention. For example,
in a nationally representative sample of persons in HIV
care in the USA, only 55 % of sexually active patients
were tested for syphilis at least once per year [21]. In
Ontario in 2009, 53 % of HIV-positive MSM received
syphilis screening or testing on average once per year
[22]. As of 2013, we observed only a modest increase in
this proportion to 64 % screened annually (unpublished
data). Although in Ontario we have observed that HIV-
positive men reporting risk behavior are more likely to
be tested, there is room for improvement; for example,
among men who reported five or more sexual partners
in the preceding 3 months, 22 % were not tested for syphilis
over the subsequent 2-year period in 2010–2013 [23].
Evidence from uncontrolled trials and observational
studies suggests that clinic-based, opt-out interventions
may improve syphilis screening coverage and case detec-
tion [24–27]. With men in HIV care, there is a practical
and relatively inexpensive opportunity to intervene be-
cause patients undergo routine blood tests for HIV viral
load every 3–6 months [28, 29]. An outpatient HIV clinic
in London, UK, added syphilis serology to computerized
routine blood order sets. Compared to a 12-month pre-
intervention period, this intervention led to an increase
from 3 to 85 % of patients receiving at least one syphilis
test, a reduction in the median time between syphilis tests
from 6 to 4 months, and a 27 % increase in the number of
early syphilis cases detected during the 12-month interven-
tion period [24]. An anal cytology screening program in an
urban Australian HIV clinic for HIV-positive MSM offered
joint STI testing, which increased bacterial STI testing (in-
cluding syphilis) from 20 to 35 % over 3 months, and they
diagnosed four new cases compared to none previously
[25]. In 2007, the Melbourne Sexual Health Centre in
Australia implemented automatic stamping of syphilis ser-
ology orders on all HIV laboratory request forms [26].
Post-intervention, the median number of tests per patient
per year rose from 1 to 2. There were also large increases
in the proportion of patients diagnosed with early syphilis
(from 3.1 to 8.1 %) and in the proportion of newly diag-
nosed cases that were asymptomatic (from 21 to 85 %). Fi-
nally, opt-in, opt-out, and risk-based clinic policies on
syphilis screening among HIV-positive MSM were com-
pared in an Australian observational cohort study at sexual
health and hospital outpatient clinics. From 2006 to 2010,
the proportion of men with at least three syphilis tests per
year was highest in clinics with an opt-out policy (48 %),
intermediate for clinics with an opt-in policy (39 %), and
was considerably lower among men who attended the
clinics with risk-based syphilis test policies (8 %) [27].
In Ontario, the majority (86 %) of syphilis tests among
people with HIV are ordered by HIV care providers [14],
suggesting that HIV clinics are the strategic target to
maximize improvements in screening. Using a Markov
model, we explored the potential cost-effectiveness of
frequent screening of HIV-positive MSM using data
from the Ontario HIV Treatment Network (OHTN) Co-
hort Study. Costs included tests, treatments, and care
for neurosyphilis and tertiary syphilis [19]. The model
predicted that more frequent screening may not only be
cost-effective but cost saving and was the preferred strat-
egy compared to usual care (57 % of the population
screening annually) when syphilis incidence was above
0.5 per 100 PY.
Burchell et al. Implementation Science  (2016) 11:8 Page 2 of 10
Based on promising intervention findings elsewhere
[24–27], local syphilis epidemiology in Ontario [14, 22,
30, 31], and current patterns of syphilis testing and diag-
nosis among HIV-positive MSM in our setting [14, 22],
we believe that a clinic-based intervention to routinize
syphilis testing with HIV viral loads could be beneficial
but that sufficient equipoise exists to warrant a trial with
a concurrent control group. The full benefit of such in-
terventions remains uncertain because previous studies
were non-randomized trials with historical controls and
with short pre- and post-intervention periods. None mea-
sured cost-effectiveness, which is essential as health sys-
tems must decide on the best use of limited resources.
The Enhanced Syphilis Screening among HIV-positive
Men (ESSAHM) trial will be the first evaluation of a
clinic-based intervention of opt-out syphilis screening
among persons with HIV using a randomized, controlled
design in multiple clinics.
Trial aim and objectives
The aim of the ESSAHM trial is to enhance syphilis
screening among HIV-positive MSM. We are conducting
a clinic-based intervention to incorporate syphilis testing
with routine HIV viral load monitoring among HIV-
positive men attending four hospital-based HIV out-
patient clinics in Toronto and Ottawa, the two largest
cities in the province of Ontario. The control condi-
tion is the maintenance of current care practices. Spe-
cific objectives are to determine to what degree the
intervention:
1. Increases the detection rate of untreated syphilis.
2. Increases the proportion of men who undergo
syphilis testing at least annually
(increased screening coverage)
3. Reduces the interval between syphilis tests
(increased screening frequency)
4. Reaches men at highest risk according to
sexual behaviors
We hypothesize that the intervention will increase the
case detection rate by 75 % or more via an increase in
screening coverage to at least 85 % and screening fre-
quency to a median of three tests per person per year.
We further hypothesize that increases in screening
coverage and frequency will be equivalent among men
regardless of sexual behavior characteristics, so that im-




We are using a pragmatic, cluster-randomized con-
trolled superiority trial using a stepped wedge design
that introduces the intervention stepwise across clinics
(Fig. 1). Clinics are randomized to one of four roll-out
schedules, each contributing at least one 6-month con-
trol period and one 6-month intervention period to the
analysis. We selected cluster randomization over indi-
vidual randomization because the intervention occurs
at the clinic level (the “cluster”), even though outcome
data is collected at the level of the individual. Unlike
parallel trials, the stepped wedge design randomly allo-
cates clusters to the order of implementation, such that
all clusters eventually implement the intervention
[32–34]. This design is recommended for pragmatic
trials when there is a strong belief that the interven-
tion will do more good than harm [34]. The stepped
wedge maximizes power compared to parallel cluster
randomized trials, requiring fewer clusters [32]. Our
approach incorporates a concurrent comparison group,
allows for assessment of time trends, and will generate
more generalizable results due to its inclusion of mul-
tiple clinics.
Fig. 1 Stepped wedge design for the Enhanced Syphilis Screening among HIV-positive Men (ESSAHM) Trial
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Study setting
We targeted settings in Ontario, Canada, where the po-
tential for benefit would be the greatest and the study
would be the most feasible. The four participating HIV
outpatient clinics are the Ottawa Hospital Immunodefi-
ciency Clinic, St. Michael’s Hospital Positive Care Clinic,
Sunnybrook Health Sciences Centre Medical Outpatient
Clinic, and Toronto General Hospital Immunodeficiency
Clinic. Toronto and Ottawa were selected because these
cities have been the epicenters of the Ontario syphilis
outbreaks over the past decade [35, 36]. The selected
clinics comprise all hospital-based HIV outpatient clinics
in these cities and 37 % of all persons receiving HIV care
in Ontario who had viral load tests submitted to the
centralized provincial laboratory in 2011 (Dr. Robert S.
Remis, personal communication, 2013-02-04). Because
interpretation of syphilis serology can be challenging, we
reasoned that initial assessment of the intervention
would be best conducted at clinics with physicians
experienced in this area. Based on data from an HIV
clinical cohort at these sites, the OHTN Cohort Study
[14, 22, 37], an estimated 78 % of persons receiving HIV
care at the participating clinics are male, of whom 73 %
are MSM. During 2014, only 43 % of MSM at these
clinics had at least one syphilis test and the median
number of tests was no higher than one, suggesting
ample opportunity to increase testing coverage and fre-
quency. Conversely, 99 % of MSM received ≥1 routine
HIV viral load test a median of three times per year,
providing an estimate of the increase in syphilis testing
expected from the intervention (Dr. Sandra Gardner,
personal communication, 2015-12-15, Ontario HIV
Treatment Network).
Study population and eligibility criteria
Rather than restricting study activities to MSM, all men
receiving HIV care at participating clinics are considered
eligible and under observation for the ESSAHM trial,
both to simplify study logistics and to minimize the need
to disclose sexual status at the time of venipuncture.
This obviates the need for repeated detailed assessments
of sexual histories [26] and is in keeping with our prag-
matic trial design. It may also maximize coverage of
men who may not have identified as MSM yet continue
to be at risk. Although the rate of syphilis among non-
MSM HIV-positive males is reported to be lower than
among those identifying as MSM, it is higher than
among women, suggesting misclassification of some
males as non-MSM [22]. Women are excluded from the
study because we have observed no new cases of syphilis
among women with HIV [22] nor are such cases being
reported in provincial surveillance; from 2002–2014,
99.9 % of all HIV and syphilis co-infected cases in On-
tario were male [38].
We will operationalize the study population as all men
in HIV care whose viral load monitoring is ordered by
physicians at the participating HIV clinics and submitted
to the centralized provincial laboratory in Ontario for
testing. Men whose viral load monitoring is exclusively
done at other sites (e.g., with a family doctor) or via par-
ticipation in industry-sponsored trials will be considered
to be outside of the study population.
Intervention and control periods
The intervention condition is opt-out standing orders
for syphilis serology whenever men undergo routine
HIV viral load tests. It is a standard practice for persons
in HIV care in these centers to undergo such tests every
3–6 months [28]. The logistics of implementing this
change in practice will be tailored to the clinic. Options
include pre-printing a checkmark for “syphilis serology”
onto existing pre-printed requisitions for routine blood
work, addition of the serology request form to the rou-
tine blood work package, or programming “syphilis ser-
ology” into existing computerized routine order sets.
Men can decline syphilis testing or request not to have
their data used for the trial at any point throughout the
study period. However, we anticipate that compliance
will be high.
The control condition is the usual syphilis testing
practices carried out by the physicians: testing may be
prompted by signs or symptoms, exposure to active
cases, men’s disclosure of sexual risk behavior, and phy-
sicians’ knowledge and experience diagnosing syphilis.
Outcomes
The primary outcome is the detection rate of new, previ-
ously untreated syphilis cases, specifically acute infec-
tious syphilis. The centralized provincial laboratory in
Ontario is the repository of all syphilis tests in Ontario,
and these will be accessed to help with syphilis diagno-
ses. This laboratory uses the following “reverse algo-
rithm” for the serologic diagnosis of syphilis: (1) screen
with chemoluminescent (CLIA) test; (2) if CLIA is re-
active or indeterminate, additional testing is performed
with the rapid plasma reagin (RPR) test as well as the
T. pallidum particle agglutination (TPPA) test for con-
firmation of CLIA screening results; (3) if RPR and
TPPA are non-reactive or indeterminate, may also in-
clude the fluorescent treponemal antibody absorbance
(FTA-Abs) test [39]. Based on this approach, a new
diagnosis is defined as:
1. Seroconversion with prior negative syphilis
serology within the previous 12 months
(requires both a reactive syphilis serological
screen and a minimum of a second reactive
syphilis test using a different serological method,
Burchell et al. Implementation Science  (2016) 11:8 Page 4 of 10
e.g., rapid plasma reagin (RPR)/T. pallidum
particle agglutination (TPPA); or
2. In men previously diagnosed with syphilis, a fourfold
or greater rise in RPR titre from the last titre within
the prior 12 months, indicative of re-infection; or
3. Clinical evidence of primary or secondary syphilis
together with laboratory confirmation (i.e., direct
fluorescent antibody or polymerase chain reaction
(PCR) from primary lesions or a positive syphilis
screening test together with a second reactive
syphilis test using a different serological method).
Diagnoses by clinical (physician ascribed) or laboratory
(at least two reactive serological results using different
methodologies) criteria which do not meet the above
definitions will be considered to be late syphilis (>1 year
since infection, non-infectious) or syphilis of unknown
duration (if date of infection not known).
Secondary outcomes include screening coverage (propor-
tion of men tested at least once per year) and screening
frequency (number of times per year).
Timeline
The data collection period will last a total of 30 months.
All clinics began with a trial run-in period in November
2014 during which there was no change in current syph-
ilis test ordering practices. The run-in allowed clinics
the opportunity to implement and pilot data collection
procedures. Feedback during the run-in was used to
modify data collection protocols as needed. After the
run-in, clinics transitioned into the first official 6-month
control period, starting in February 2015, with no
change to syphilis testing practices from the status quo.
At the end of this period (August 2015), the intervention
was implemented at the first clinic as randomly assigned
within the stepped wedge (Fig. 1). At the end of each 6-
month period, a new clinic will implement the inter-
vention according to their placement on the wedge. By
July 2017, all clinics will have implemented the inter-
vention for a minimum of 6 months. Figure 2 outlines
the timeline and procedures for data collection.
Sample size and power
We used two approaches to anticipate power to detect
a ≥75 % increase in our primary outcome, the case de-
tection rate based on the effect size reported in pre-/
post-intervention studies [24, 26]. First, using a pub-
lished method for stepped wedge designs [32], we
calculated that we could detect a ≥60 % increase in case
detection, assuming an overall baseline case detection
rate of 2.5 % [14], a sample size of 2278 men from four
sites, the stepped wedge design (Fig. 2), 80 % power, a
significance level of 0.05, and a within-clinic intraclass
correlation coefficient of 0.004 (OHTN Cohort Study,
unpublished data). However, that approach assumes in-
dependence of observations across time periods [32].
Following a cohort population such as in the ESSAHM
trial violates that assumption because the same subject
may appear in more than one time period, introducing
within-subject correlation [33, 40, 41]. Therefore, we
ran extensive simulations to account for within-clinic
and within-subject correlation. Under varying assump-
tions, the simulations demonstrated that a sample size
of 2278 men will provide at least 80 % power to detect
a ≥75 % increase in the case detection rate (from 2.5 to
Beginning of 6 month control period: 
current care practice (t = months 0-6)
Included in study population: HIV+ 
men attending participating clinic for 
routine HIV care
Excluded: Women
Completion of clinical worksheets for all 
reactive syphilis serologies
End of 6 month study period
Chart abstraction, collection of 
management events for new 
cases, data entry
Trial run-in period
Beginning of randomly selected 6 month study period 
Control period: current care practice 
OR
Intervention period: standing orders for syphilis serology when undergoing HIV 
follow-up bloodwork
Repeated 3 additional times (t=months 6-30)
Fig. 2 Participant data collection timeline and procedures in the ESSAHM Trial
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4.4 % or higher). Anticipated power is 90 % or greater to
detect changes in both secondary outcomes (screening
coverage from 55 to 85 %; screening frequency from one
test/year to three tests/year).
Assignment of intervention
At month 5, we used blinded, random allocation to as-
sign each clinic to the order of implementation on the
wedge (Fig. 1). Randomization was performed by a bio-
statistician who was not a member of the project team
and who was blinded to clinic names. Once complete,
clinic allocation was unblinded to the project team.
Data collection and management
Baseline data to characterize the study population in-
clude age, number of viral loads ordered in the preceding
12 months, and ever had a requisition for HIV resistance
testing/genotyping post initiation of antiretroviral therapy
(proxy measure of history of significant virologic failure)
and syphilis test history (any past linked syphilis test since
2010 ordered by (i) the clinic and (ii) any Ontario care
provider; any past reactive syphilis test since 2010 ordered
by (i) the clinic and (ii) any Ontario care provider).
Follow-up data will then be appended for each 6-month
period: all HIV viral loads and syphilis serology tests or-
dered by the participating clinics (test dates and results);
any viral load ordered by another health care provider in
Ontario (month and year of test); and any syphilis serology
test ordered by another health care provider in Ontario
(month and year of test).
Positive syphilis serology results at the centralized pro-
vincial laboratory in Ontario will be supplemented with
clinical diagnostic data recorded in patient charts. We
developed a standardized clinical worksheet as a tool to
aid nurses and physicians in determining which reactive
syphilis tests require further follow-up, including a brief,
standardized set of questions to facilitate syphilis staging
(Online Supplemental Content). The worksheet was pre-
tested in all clinics and revised to adequately capture
most anticipated situations. In our experience, 40–80 %
of syphilis cases can be assigned a stage based on retro-
spective chart review [8, 22]; the clinical worksheets will
further improve this figure. At periodic intervals, an ana-
lyst at the centralized provincial laboratory will send to
each clinic a batched list of all men receiving HIV care
with reactive syphilis results. This will prompt medical
chart reviewers at the clinics to enter data from the clinical
worksheets and patient charts for all screen test positives
into a Microsoft Access database with standardized elec-
tronic case report forms. Data integrity mechanisms and
reviewer training promote data quality.
Additional clinical, psychosocial, and behavioral data
will be available for a subset of men receiving HIV care
who are also participants in an ongoing clinical cohort,
the OHTN Cohort Study. Its design is fully described
elsewhere [14, 22, 37]. Briefly, volunteer participants are
attending specialty HIV clinics across Ontario (including
all four study sites), are aged 16 years and older, and
provide written informed consent. Clinical and sociobe-
havioral data is collected through clinical chart review,
annual interviews, and via record linkage with test data
at the centralized provincial laboratory in Ontario. Ap-
proximately 40 % of persons receiving HIV care at the
four ESSAHM trial clinics are active cohort participants
[14, 22, 37]. Participation rates are 20 % higher among
MSM [42]. The cohort collects data using medical
chart abstractions and an annual interview with a self-
administered sexual behavior questionnaire. Measures
of sexual behavior in the preceding 3 months include
biological sex and number of sexual partners, nature
of relationship (regular versus casual), HIV status of
partners, and whether the participant engaged in anal
intercourse with or without a condom.
Statistical methods
The analysis will consist of three stages. First, we will as-
sess characteristics of the clinics, men receiving HIV
care, and the subgroup of OHTN Cohort Study partici-
pants at baseline. Second, we will conduct interim pre-
liminary analysis for assessment of the intervention
effect and temporal trends at month 18. Finally, we will
conduct comparisons between control and intervention
periods using intention-to-treat principles at the end of
the study period (month 30), once all clinics have had at
least one 6-month intervention period.
Outcomes will be summarized across sites for each
time period and between control and intervention time
periods within sites. We will use tabular and graphical
summaries to describe demographic, behavioral, and clin-
ical characteristics of the participants within and across
sites and over time. We will check for delayed treatment
effects to evaluate the assumption that the 6-month time
periods are long enough to see the full intervention effect.
We will estimate the intervention effect using general
linear mixed models (Table 1). Models will take into ac-
count within and between site variance components,
within-subject correlation, and will have random site ef-
fects, a fixed time effect and a fixed effect due to the
intervention. With only four clinics in the trial, there
may be differences in clinic populations that may con-
found the intervention effect. Therefore, patient-level
covariates will be added to the model (i.e., baseline age,
viral load, and syphilis test histories) if necessary to adjust
for measurable differences in patient populations across
clinics and time periods. In the sub-analysis among men
receiving HIV care who are participants of the OHTN
Cohort Study, we will additionally include covariates such
as sociodemographic characteristics and sexual behaviors
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if these are empirical confounders of the intervention effect.
To determine whether the intervention effects on screening
coverage and frequency are equivalent among men across
sexual behavior characteristics, we will test for statistical in-
teractions between the fixed effect due to the intervention
and sexual behavior variables.
Additional planned analysis
Using exploratory analyses, we will characterize trends
in syphilis testing outside of the confines of the study
population and the ESSAHM trial intervention. First,
among men in the study population, we will document
trends in syphilis testing ordered by providers external
to participating clinics according to records at the cen-
tralized provincial laboratory in Ontario. Second, we will
track rates of syphilis test ordering by participating
clinics for clinic patients who are not part of the defined
study population. We will also follow public health sur-
veillance case reports to note whether there is ecologic
evidence of changes in syphilis diagnosis rates over the
study period.
Process evaluation
We will calculate the proportion of submitted viral loads
that have a corresponding requisition for syphilis serology.
Qualitatively, debriefing discussions with site clinicians
will help identify reasons for any absence of syphilis
serology with HIV blood work. Discussion points that
arise during debriefing sessions (particularly any of con-
cern to men receiving HIV care) will be brought forth and
addressed by the Trial Steering Committee, which in-
cludes community representatives. In addition, at the end
of the 6-month implementation period at each clinic, we
will conduct open-ended qualitative interviews with health
care providers about their experiences with the interven-
tion, including perceptions of its utility, convenience,
barriers and facilitators to implementation, and opinions
on long-term sustainability.
Economic evaluation
The economic evaluation will be conducted in two steps.
Direct and indirect costing of each additional syphilis
diagnosis will be estimated using Ontario’s public-payer
fee schedules for outpatient services, the Canadian Insti-
tute for Health Information cost database by case-mix
group for inpatient services, the Ontario Drug Benefit
wholesale prices for drug costs, and the wholesale pur-
chase of test kits and technician time at the centralized
provincial laboratory in Ontario. Additional costs will be
drawn from the published literature [43, 44]. We will
calculate costs for the intervention as a whole and indi-
vidually for each syphilis diagnosis in the intervention
and control periods.
In step 1, we will use a net-benefit regression framework
to produce the cost-effectiveness acceptability curves,
where the y-axis represents the probability of the inter-
vention being cost-effective and the x-axis represents the
willingness to pay [45]. This will be a simple calculation
using linear regression with bootstrapping for sensitivity
analyses.
In step 2, we will use a dynamic mathematical model
of syphilis and HIV transmission among Ontario
MSM using the trial data to estimate the projected in-
cremental health benefits (quality of life years gained)
per additional cost of identifying new syphilis cases,
when examined from a health-provider perspective.
Ethics
The ESSAHM trial protocol has been approved by the
Research Ethics Boards at Ottawa Health Science Network,
St. Michael’s Hospital, Sunnybrook Health Sciences Centre,
Table 1 Variables, measures, and methods of analysis for ESSAHM trial
Variable/outcome Hypothesis Outcome measure Methods of analysis
1) Primary: syphilis case detection 75 % increase over baseline rate New, previously untreated
syphilis case as a binary
measure
GLMM models using SAS PROC
GLIMMIX with logit function
2) Secondary:a. screening coverage Increase to 85 % of men testing
annually
Tested one or more times in
6-month study period as a
binary measure
GLMM models using SAS PROC
GLIMMIX with logit function
Compare proportion tested and
modify to annualized rates
b. screening frequency Increase to median of 3 tests per
person/year
Number of tests per year
as Poisson count
outcome data
GLMM models using SAS PROC
GLIMMIX with log link function
c. reached men at highest risk for
syphilis by examining OHTN Cohort
Studya subgroup
Increases in screening coverage
and frequency (2a&b) occur in the
among men at highest risk for syphilis




GLMM models using SAS PROC
GLIMMIX with logit and log link
function
GLMM general linear mixed models
aOntario HIV Treatment Network Cohort Study, an ongoing clinical HIV cohort taking place at the four participating clinics of the trial [37]. An estimated 40 % of
men in HIV care at these clinics are active participants of that cohort
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University Health Network, University of Toronto, and
Public Health Ontario. The trial is registered at Clinical-
Trials.gov (NCT02019043).
As each clinic implements the intervention, multiple
strategies will be used to inform males receiving HIV
care that the clinic is participating in the ESSAHM trial
using an “opt-out” model. All participants will receive infor-
mation about the study and provide verbal consent. How-
ever, written consent is not required, in keeping with the
Canadian Tri-Council Policy Statement (TCPS2) Articles
3.7 to 3.11 and the Ontario Personal Health Information
Protection Act 44, 3c and d [46]. Health care providers
will discuss the trial and circulate posters and bro-
chures informing men about the study, the right to opt-
out and how to opt-out. At any time, men receiving
HIV care can opt-out of syphilis testing and/or refuse
to have their clinical data used for the trial by simply
telling their health care provider that they wish not to
be included.
The risks associated with the ESSAHM trial are modest.
First, although syphilis testing requires the additional col-
lection of 7 mL of blood, there will be negligible additional
health risk to men receiving HIV care because separate
venipuncture is not required. Second, there is a theoret-
ical risk of over-treatment due to false positive syphilis
serology results, particularly for low-risk men. However,
the risk of over-treatment will be mitigated by clinical
judgment that takes into account self-reported sexual
behavior and past history of syphilis test results in making
the final determination whether to treat, and more fre-
quent syphilis testing will help clarify syphilis history. Fur-
ther, a syphilis diagnosis may cause men stress, anxiety,
and fear of stigmatization; such risks will be mitigated via
appropriate counseling by physicians and the high success
rate of syphilis treatments.
Data confidentiality and access
At the clinics, participant information will either be se-
curely stored in patient charts or locked file cabinets in
areas with limited access. To maintain confidentiality of
men in the study, all will be given a “Case ID” and no
personal identifying information will be entered into the
study database. Extractions at the centralized provincial
laboratory in Ontario will be performed by authorized
personnel and stored in a secure network environment
with limited access. Information sent to the clinics will
be faxed using a secure fax system. When data are trans-
ferred from the laboratory and clinics to the investigating
team for analysis, they will be de-identified, encrypted,
and sent through a secure server. Data will be stored on
password-protected computers located in a secure server
environment. They will remain encrypted when not in
use. Access will be restricted to members of the study
team who will sign confidentiality agreements. Data will
never be reported in groups of less than five individuals in
any cell or data block to further guard against the inad-
vertent disclosure of identities.
Dissemination
Results of the ESSAHM trial will be reported according
to a pre-determined publication policy approved by all
members of the research team. Study results will be dis-
seminated via scientific conferences and publications;
presentations to public health working groups, health
care providers, and community symposia for men living
with HIV; and meetings with decision-makers.
Trial status
The ESSAHM trial run-in period began in November
2014, and the official start date was February 2015. Data
collection will continue until July 2017.
Discussion
Syphilis diagnoses occur at a rate of 3.3 per 100 PY
among HIV-positive men in Ontario [14], yet testing in
this population remains below recommended guidelines
[6, 17, 18]. Routinizing syphilis testing with regular HIV
blood work has shown potential to improve case detec-
tion in uncontrolled studies. However, a randomized,
controlled, pragmatic, multi-center trial is needed to
firmly establish the public health impact and cost-
effectiveness of this approach. The ESSAHM trial design
maximizes rigor within the practical constraints of our
setting. We opted for a pragmatic approach consistent
with “real life” conditions if the centralized provincial la-
boratory in Ontario were to routinize syphilis testing
with viral loads at regional or provincial levels.
There are potential threats to validity for which we will
remain vigilant. As of June 2015, syphilis case reporting
remained high in Ontario [38]. Nevertheless, secular
trends in syphilis testing and/or incidence may result in
the intervention being more or less effective than antici-
pated. In an era where viral load monitoring may be-
come less frequent for persons in HIV care who are on a
stable, fully suppressive antiretroviral treatment regimen
[28], the realized benefits of an opt-out screening pro-
gram attached to HIV viral load testing may lessen over
time. The stepped wedge design will allow for assess-
ment of underlying time trends [34] which should miti-
gate bias due to secular changes. As for other screening
interventions, case detection may be initially high due to
diagnosis of prevalent cases but may then decrease as
only incident cases remain; we will be able to quantify
such trends for those clinics randomized to earlier imple-
mentation of the intervention. The trial involves investiga-
tors who are practicing clinicians at the participating sites,
which could introduce a Hawthorne effect; nevertheless,
each clinic also includes several non-study physicians.
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Although it is a multi-site trial, it involves only four clinics
and excludes persons receiving HIV care whose viral
loads are monitored elsewhere. Detailed description of
the trial population, setting, and local contexts will
allow for future assessments regarding generalizability
to other populations.
Lessons learned from the ESSAHM trial will guide
policy and practice decisions regarding scale-up in these
and other HIV clinics in Ontario and at the centralized
provincial laboratory. Members of the team (DHST, PM,
SM) are also conducting studies to determine the most
appropriate management strategies for syphilis/HIV co-
infected persons in HIV care. Results will contribute to
comprehensive, evidence-based recommendations on
policies, practices, and strategies to reduce syphilis bur-
den among MSM. Moreover, knowledge gained on the
potential benefit of syphilis screening interventions from
the ESSAHM trial may be applicable to other sexually
transmitted and blood-borne infections that pose risk
for men receiving HIV care, including chlamydia, gonor-
rhea, and hepatitis viruses.
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